Equol Clinicals & Studies


A clinical study examining the efficacy of Equol in treating BPH was conducted in 2013. The study examined Equol treatment of healthy middle aged men with moderate to severe symptoms associated with BPH. Dosing was 6 mg, twice per day for four weeks. Plasma Equol levels were measured and are shown below.  Each subject underwent blood sample collection prior to taking the oral Equol supplement in the clinic and approximately 40-60 minutes after taking the Equol supplement for visit 1 and visit 3 (the 4th week of Equol treatment or the end of the study).  Subjects received a two-week supply of the Equol supplement and were instructed to take 1 oral supplement twice per day with food (at breakfast and dinner). The circulating Equol concentrations were found to be consistent with previous reports.

Equol is Bioavailable, Concentrates in the Prostate, is a Potent Anti-Oxidant, and Crosses the Blood Brain Barrier


Clinical Efficacy, International Prostate Symptom Score (IPPS)

The primary efficacy measure was the IPSS questionnaire comparing baseline to 2 and 4 weeks. Six milligrams of Equol, twice-per-day positively improved moderate to severe BPH symptoms according to the IPSS indices. In moderately symptomatic men (n = 10) 5 out of 7 of the IPSS parameters significantly improved by 4 weeks of Equol treatment. In severely symptomatic men (n = 8) all 7 of the IPSS parameters significantly improved with 4 weeks of Equol treatment.




  1. Lephart ED.  2013.  Severe and moderate BPH symptoms in mid-aged men improved with isoflavonoid-Equol treatment: Pilot intervention study. Open Journal Urology 3:21-27.
  2. Lephart, ED. 2014.  Review: Anti-Oxidant and Anti-Aging Properties of Equol in Prostate Health (BPH). Open Journal of Endocrine and Metabolic Diseases 4, 1-12.
  3. Prins GS, Korach KS. 2008. The Role of Estrogens and Estrogen Receptors in Normal Prostate Growth and Disease. Steroids 73(3): 233–244.
  4. Lund TD, Munson DJ, Haldy ME, Setchell KDR, Lephart ED, Handa RJ.  2004.  Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod 70:1188-1195.
  5. Fujimura T, Takahashi S, Urano T, Ijichi N, Kumagai J, Murata T, Takayama K, Horie-Inoue K, Ouchi Y, Muramatsu M, Homma Y, Inoue S.  2010.  Differential expression of estrogen-related receptors beta and gamma (ERRbeta and ERRgamma) and their clinical significance in human prostate cancer. Cancer Science 101(3):646-651.
  6. Hamilton-Reeves JM, Rebello SA, Thomas W.  2007.  Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-β expression or serum hormonal profiles in men at high risk of prostate cancer. Journal of Nutrition 137(7):1769-1775.
  7. Hedlund TE, Maroni PD, Ferucci PG, Dayton R, Barnes S, Jones K, Moore R, Ogden LG, Wahala K, Sackett HM, Gray KJ.  2005.  Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in Causasian men. J Nutr 135:1400-1406.
  8. Gardner CD, Oelrich B, Liu JP, Feldman D, Franke AA, Brooks JD.  2009.  Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation.  Prostate 69(7):719-726.
  9. Ellem SJ and Risbridger GP. 2009.  The dual, opposing role of estrogens in the prostate. Annals New York Academy of Science 1155:174-186.